SNGX
Soligenix, Inc.
There isn't enough reported data to score SNGX yet.
SNGX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
SNGX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
SNGX PE Valuation
SNGX has no meaningful PE right now: it lost money over the past year.
SNGX Forward outlook
There aren't enough analyst estimates for SNGX to show an outlook.
SNGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$31.84 | +$52.16 |
| Q2 2023 | -$48.48 | +$37.92 |
| Q1 2023 | -$58.72 | +$25.28 |
| Q4 2022 | -$76.96 | -$2.56 |
| Q3 2022 | -$84.00 | +$2.40 |
| Q2 2022 | -$86.40 | -$7.20 |
| Q1 2022 | -$84.00 | +$7.20 |
| Q4 2021 | -$74.40 | +$79.20 |
SNGX is still losing money, but far less than before: $5.17 per share over the past year, against $170.40 at its worst in early 2020.
SNGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2024 | $2.3K | -99% |
| Q1 2024 | $117K | -54% |
| Q4 2023 | $244.8K | -33% |
| Q3 2023 | $130.4K | -21% |
| Q2 2023 | $206.9K | -9.5% |
| Q1 2023 | $257.2K | +37% |
| Q4 2022 | $366.1K | +33% |
| Q3 2022 | $166.1K | -11% |
SNGX's revenue has slid since its 2020 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2024 | -74495% | -73707 points |
| Q1 2024 | -1809% | -973 points |
| Q4 2023 | -873% | +102 points |
| Q3 2023 | -1364% | +491 points |
| Q2 2023 | -788% | +697 points |
| Q1 2023 | -836% | +1398 points |
| Q4 2022 | -975% | +665 points |
| Q3 2022 | -1855% | -42 points |
SNGX's operating margin was −74495% last quarter, down 73707 points from the same quarter a year ago, near the bottom of its range since 2019.
SNGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.4M | -$510.7K |
| Q4 2025 | -$2.7M | -$514.2K |
| Q3 2025 | -$2.9M | -$22.8K |
| Q1 2025 | -$1.8M | -$504.5K |
| Q4 2024 | -$2.2M | -$404.6K |
| Q3 2024 | -$2.9M | -$224.1K |
| Q2 2024 | -$1.9M | +$5.5K |
| Q1 2024 | -$1.3M | +$823.8K |
SNGX has burned cash in almost every quarter: −$10M over the past year, against −$8M the year before.
SNGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +39% | +6.2M shares |
| 1 year | +576% | +18.9M shares |
| 3 years | +12241% | +22M shares |
| 5 years | +17874% | +22M shares |
SNGX has 22M diluted shares, up 576% from a year ago.
SNGX Net Leverage
SNGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SNGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 17.2 | Oversold |
SNGX's weekly RSI is 35 (neutral) and its Stochastic is 17 (oversold).
SNGX PE vs Healthcare Sector
SNGX has no meaningful PE right now: it lost money over the past year.
SNGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.36 | 11% below |
| 20 week MA | $0.37 | 14% below |
| 50 week MA | $0.77 | 58% below |
| 100 week MA | $1.44 | 78% below |
| 200 week MA | $8.25 | 96% below |
SNGX is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
SNGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $340.8 | $321.6 | -5.6% |
| 2021 | $321.6 | $184.3 | -43% |
| 2022 | $184.3 | $154.9 | -16% |
| 2023 | $154.9 | $12.1 | -92% |
| 2024 | $12.1 | $2.89 | -76% |
| 2025 | $2.89 | $1.37 | -53% |
| 2026 YTD | $1.37 | $0.32 | -77% |
SNGX has finished every year since 2020 lower, and it's down 77% so far in 2026.